MA55558A - Anticorps anti-cd73, anti-pd-l1 et chimiothérapie de traitement de tumeurs - Google Patents
Anticorps anti-cd73, anti-pd-l1 et chimiothérapie de traitement de tumeursInfo
- Publication number
- MA55558A MA55558A MA055558A MA55558A MA55558A MA 55558 A MA55558 A MA 55558A MA 055558 A MA055558 A MA 055558A MA 55558 A MA55558 A MA 55558A MA 55558 A MA55558 A MA 55558A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- tumor treatment
- treatment chemotherapy
- chemotherapy
- tumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962828177P | 2019-04-02 | 2019-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55558A true MA55558A (fr) | 2022-02-09 |
Family
ID=72663659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055558A MA55558A (fr) | 2019-04-02 | 2020-04-01 | Anticorps anti-cd73, anti-pd-l1 et chimiothérapie de traitement de tumeurs |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200317803A1 (fr) |
EP (1) | EP3947447A4 (fr) |
JP (1) | JP2022527334A (fr) |
KR (1) | KR20210148253A (fr) |
CN (1) | CN113993890A (fr) |
AU (1) | AU2020254100A1 (fr) |
CA (1) | CA3134671A1 (fr) |
EA (1) | EA202192587A1 (fr) |
IL (1) | IL286504A (fr) |
MA (1) | MA55558A (fr) |
SG (1) | SG11202110694RA (fr) |
TW (1) | TW202102545A (fr) |
WO (1) | WO2020202038A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023201267A1 (fr) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Polythérapie pour le traitement de cancers exprimant trop-2 |
WO2023227115A1 (fr) * | 2022-05-26 | 2023-11-30 | I-Mab Biopharma Co., Ltd. | Procédé de traitement d'une tumeur solide |
WO2024116140A1 (fr) * | 2022-12-01 | 2024-06-06 | Medimmune Limited | Polythérapie comprenant des anticorps anti-pd-l1 et anti-cd73 pour le traitement du cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3218406T (pt) * | 2014-11-10 | 2021-06-17 | Medimmune Ltd | Moléculas de ligação específicas para cd73 e seus usos |
SG10201913033UA (en) * | 2016-03-04 | 2020-03-30 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
CA3033542A1 (fr) * | 2016-08-30 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Compositions et utilisations de biomateriaux et d'activateurs de l'immunite innee |
CN110785187B (zh) * | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
-
2020
- 2020-04-01 TW TW109111394A patent/TW202102545A/zh unknown
- 2020-04-01 EP EP20783214.8A patent/EP3947447A4/fr active Pending
- 2020-04-01 US US16/837,477 patent/US20200317803A1/en active Pending
- 2020-04-01 KR KR1020217035422A patent/KR20210148253A/ko unknown
- 2020-04-01 MA MA055558A patent/MA55558A/fr unknown
- 2020-04-01 EA EA202192587A patent/EA202192587A1/ru unknown
- 2020-04-01 CA CA3134671A patent/CA3134671A1/fr active Pending
- 2020-04-01 AU AU2020254100A patent/AU2020254100A1/en active Pending
- 2020-04-01 JP JP2021558768A patent/JP2022527334A/ja active Pending
- 2020-04-01 WO PCT/IB2020/053110 patent/WO2020202038A1/fr unknown
- 2020-04-01 CN CN202080039845.5A patent/CN113993890A/zh active Pending
- 2020-04-01 SG SG11202110694RA patent/SG11202110694RA/en unknown
-
2021
- 2021-09-19 IL IL286504A patent/IL286504A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210148253A (ko) | 2021-12-07 |
EA202192587A1 (ru) | 2022-01-13 |
JP2022527334A (ja) | 2022-06-01 |
TW202102545A (zh) | 2021-01-16 |
IL286504A (en) | 2021-10-31 |
US20200317803A1 (en) | 2020-10-08 |
WO2020202038A1 (fr) | 2020-10-08 |
AU2020254100A1 (en) | 2021-11-18 |
CN113993890A (zh) | 2022-01-28 |
SG11202110694RA (en) | 2021-10-28 |
CA3134671A1 (fr) | 2020-10-08 |
EP3947447A1 (fr) | 2022-02-09 |
EP3947447A4 (fr) | 2023-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
MA51208A (fr) | Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer | |
MA47208A (fr) | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
MA42447A (fr) | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation | |
EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
MA43859A (fr) | Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
MA55868A (fr) | Anticorps monoclonal anti-ctla4 ou son fragment se liant à l'antigène, composition pharmaceutique et son utilisation | |
MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
MA55558A (fr) | Anticorps anti-cd73, anti-pd-l1 et chimiothérapie de traitement de tumeurs | |
MA52285A (fr) | Anticorps multispécifiques et leur utilisation | |
MA41375A (fr) | Anticorps igg bispécifiques et leurs procédés de préparation | |
MA43738A (fr) | Anticorps anti-tnfalpha et leurs fragments fonctionnels | |
MA50038A (fr) | Anticorps anti-pd-l1 de et son utilisation | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
MA44777A (fr) | Anticorps humanisés anti-basigine et leur utilisation | |
MA52190A (fr) | Anticorps anti-trem-1 et utilisations associées | |
EP3877418A4 (fr) | Schéma posologique d'anticorps anti-tigit pour le traitement du cancer |